Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach

Madrigal Pharmaceuticals sustains strong commercial momentum with Rezdiffra, even amid new competition from semaglutide.

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Madrigal Pharmaceuticals, Inc. ( MDGL) Canaccord Genuity's 46th Annual Growth Conference August 11, 2026 12:00 PM EDT ...
FiercePharma

Madrigal's Rezdiffra off to strong start, but 'bumpiness' is coming: analyst

In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. The ...
Nasdaq

Madrigal Pharmaceuticals Reports Significant Two-Year Results for Rezdiffra in Compensated MASH Cirrhosis Patients

Patients in the Phase 3 MAESTRO-NAFLD-1 trial achieved a statistically significant mean reduction of 6.7 kPa in liver stiffness, the largest reported in compensated MASH cirrhosis populations. 51% of ...
Yahoo Finance

The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data Release

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
clinicaladvisor.com

Rezdiffra for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic ...
Nasdaq

Madrigal Pharmaceuticals Reports Positive Two-Year Results for Rezdiffra in Phase 3 MAESTRO-NAFLD-1 Trial for MASH Cirrhosis

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...